MovDisordV3, PascalFrancis, Corpus, bibRecord, 001086

Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism

Identifieur interne : 001086 ( PascalFrancis/Corpus ); précédent : 001085; suivant : 001087

Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism

Auteurs : John G. Nutt ; Steven A. Gunzler ; Trish Kirchhoff ; Penelope Hogarth ; Jerry L. Weaver ; Michael Krams ; Brenda Jamerson ; Frank S. Menniti ; Jaren W. Landen

Source :

Movement disorders [ 0885-3185 ] ; 2008.

RBID : Pascal:08-0522202

Descripteurs français

Pascal (Inist)
- Dyskinésie, Parkinsonisme, Maladie de Parkinson, Amnésie, Pathologie du système nerveux, NMDA, Glutamate, Lévodopa, Sousunité NR2B.

English descriptors

KwdEn :
- Amnesia, Dyskinesia, Glutamate, Levodopa, NMDA, Nervous system diseases, Parkinson disease, Parkinsonism.

Abstract

Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101,606, on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101,606 reduced the maximum severity of levodopa-induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 23`
A06				`@2 13`
A08	`01`	`1`	`ENG`	`@1 Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism`
A11	`01`	`1`		`@1 NUTT (John G.)`
A11	`02`	`1`		`@1 GUNZLER (Steven A.)`
A11	`03`	`1`		`@1 KIRCHHOFF (Trish)`
A11	`04`	`1`		`@1 HOGARTH (Penelope)`
A11	`05`	`1`		`@1 WEAVER (Jerry L.)`
A11	`06`	`1`		`@1 KRAMS (Michael)`
A11	`07`	`1`		`@1 JAMERSON (Brenda)`
A11	`08`	`1`		`@1 MENNITI (Frank S.)`
A11	`09`	`1`		`@1 LANDEN (Jaren W.)`
A14	`01`			`@1 Department of Neurology, Oregon Health and Science University @2 Portland, Oregon @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A14	`02`			`@1 Pfizer Global Research and Development @2 Groton, Connecticut @3 USA @Z 5 aut. @Z 6 aut. @Z 8 aut. @Z 9 aut.`
A14	`03`			`@1 VA Medical Center Geriatric Research, Education and Clinical Center and Department of Clinical Research, Campbell University School of Pharmacy @2 Morrisville, NC @3 USA @Z 7 aut.`
A20				`@1 1860-1866`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000184468160100`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 32 ref.`
A47	`01`	`1`		`@0 08-0522202`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101,606, on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101,606 reduced the maximum severity of levodopa-induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B02U01`
C03	`01`	`X`	`FRE`	`@0 Dyskinésie @5 01`
C03	`01`	`X`	`ENG`	`@0 Dyskinesia @5 01`
C03	`01`	`X`	`SPA`	`@0 Disquinesia @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinsonisme @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinsonism @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson síndrome @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Amnésie @5 04`
C03	`04`	`X`	`ENG`	`@0 Amnesia @5 04`
C03	`04`	`X`	`SPA`	`@0 Amnesia @5 04`
C03	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 05`
C03	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 05`
C03	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 05`
C03	`06`	`X`	`FRE`	`@0 NMDA @5 09`
C03	`06`	`X`	`ENG`	`@0 NMDA @5 09`
C03	`06`	`X`	`SPA`	`@0 NMDA @5 09`
C03	`07`	`X`	`FRE`	`@0 Glutamate @2 NK @2 FX @5 10`
C03	`07`	`X`	`ENG`	`@0 Glutamate @2 NK @2 FX @5 10`
C03	`07`	`X`	`SPA`	`@0 Glutamato @2 NK @2 FX @5 10`
C03	`08`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 11`
C03	`08`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 11`
C03	`08`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 11`
C03	`09`	`X`	`FRE`	`@0 Sousunité NR2B @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Aminoacide excitateur @5 37`
C07	`01`	`X`	`ENG`	`@0 Excitatory aminoacid @5 37`
C07	`01`	`X`	`SPA`	`@0 Aminoácido excitador @5 37`
C07	`02`	`X`	`FRE`	`@0 Neurotransmetteur @5 38`
C07	`02`	`X`	`ENG`	`@0 Neurotransmitter @5 38`
C07	`02`	`X`	`SPA`	`@0 Neurotransmisor @5 38`
C07	`03`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 39`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 39`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 39`
C07	`04`	`X`	`FRE`	`@0 Mouvement involontaire @5 40`
C07	`04`	`X`	`ENG`	`@0 Involuntary movement @5 40`
C07	`04`	`X`	`SPA`	`@0 Movimiento involuntario @5 40`
C07	`05`	`X`	`FRE`	`@0 Trouble neurologique @5 42`
C07	`05`	`X`	`ENG`	`@0 Neurological disorder @5 42`
C07	`05`	`X`	`SPA`	`@0 Trastorno neurológico @5 42`
C07	`06`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 43`
C07	`06`	`X`	`ENG`	`@0 Cerebral disorder @5 43`
C07	`06`	`X`	`SPA`	`@0 Encéfalo patología @5 43`
C07	`07`	`X`	`FRE`	`@0 Maladie dégénérative @5 44`
C07	`07`	`X`	`ENG`	`@0 Degenerative disease @5 44`
C07	`07`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 44`
C07	`08`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 45`
C07	`08`	`X`	`ENG`	`@0 Central nervous system disease @5 45`
C07	`08`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 45`
C07	`09`	`X`	`FRE`	`@0 Trouble de la mémoire @5 46`
C07	`09`	`X`	`ENG`	`@0 Memory disorder @5 46`
C07	`09`	`X`	`SPA`	`@0 Trastorno memoria @5 46`
C07	`10`	`X`	`FRE`	`@0 Trouble cognitif @5 47`
C07	`10`	`X`	`ENG`	`@0 Cognitive disorder @5 47`
C07	`10`	`X`	`SPA`	`@0 Trastorno cognitivo @5 47`
N21				`@1 343`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0522202 INIST
ET :	Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism
AU :	NUTT (John G.); GUNZLER (Steven A.); KIRCHHOFF (Trish); HOGARTH (Penelope); WEAVER (Jerry L.); KRAMS (Michael); JAMERSON (Brenda); MENNITI (Frank S.); LANDEN (Jaren W.)
AF :	Department of Neurology, Oregon Health and Science University/Portland, Oregon/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut.); Pfizer Global Research and Development/Groton, Connecticut/Etats-Unis (5 aut., 6 aut., 8 aut., 9 aut.); VA Medical Center Geriatric Research, Education and Clinical Center and Department of Clinical Research, Campbell University School of Pharmacy/Morrisville, NC/Etats-Unis (7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 13; Pp. 1860-1866; Bibl. 32 ref.
LA :	Anglais
EA :	Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101,606, on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101,606 reduced the maximum severity of levodopa-induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects.
CC :	002B17; 002B02U01
FD :	Dyskinésie; Parkinsonisme; Maladie de Parkinson; Amnésie; Pathologie du système nerveux; NMDA; Glutamate; Lévodopa; Sousunité NR2B
FG :	Aminoacide excitateur; Neurotransmetteur; Syndrome extrapyramidal; Mouvement involontaire; Trouble neurologique; Pathologie de l'encéphale; Maladie dégénérative; Pathologie du système nerveux central; Trouble de la mémoire; Trouble cognitif
ED :	Dyskinesia; Parkinsonism; Parkinson disease; Amnesia; Nervous system diseases; NMDA; Glutamate; Levodopa
EG :	Excitatory aminoacid; Neurotransmitter; Extrapyramidal syndrome; Involuntary movement; Neurological disorder; Cerebral disorder; Degenerative disease; Central nervous system disease; Memory disorder; Cognitive disorder
SD :	Disquinesia; Parkinson síndrome; Parkinson enfermedad; Amnesia; Sistema nervioso patología; NMDA; Glutamato; Levodopa
LO :	INIST-20953.354000184468160100
ID :	08-0522202

Links to Exploration step

Pascal:08-0522202

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism</title>
<author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gunzler, Steven A" sort="Gunzler, Steven A" uniqKey="Gunzler S" first="Steven A." last="Gunzler">Steven A. Gunzler</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kirchhoff, Trish" sort="Kirchhoff, Trish" uniqKey="Kirchhoff T" first="Trish" last="Kirchhoff">Trish Kirchhoff</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hogarth, Penelope" sort="Hogarth, Penelope" uniqKey="Hogarth P" first="Penelope" last="Hogarth">Penelope Hogarth</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weaver, Jerry L" sort="Weaver, Jerry L" uniqKey="Weaver J" first="Jerry L." last="Weaver">Jerry L. Weaver</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Krams, Michael" sort="Krams, Michael" uniqKey="Krams M" first="Michael" last="Krams">Michael Krams</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jamerson, Brenda" sort="Jamerson, Brenda" uniqKey="Jamerson B" first="Brenda" last="Jamerson">Brenda Jamerson</name>
<affiliation><inist:fA14 i1="03"><s1>VA Medical Center Geriatric Research, Education and Clinical Center and Department of Clinical Research, Campbell University School of Pharmacy</s1>
<s2>Morrisville, NC</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menniti, Frank S" sort="Menniti, Frank S" uniqKey="Menniti F" first="Frank S." last="Menniti">Frank S. Menniti</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Landen, Jaren W" sort="Landen, Jaren W" uniqKey="Landen J" first="Jaren W." last="Landen">Jaren W. Landen</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0522202</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0522202 INIST</idno>
<idno type="RBID">Pascal:08-0522202</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001086</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism</title>
<author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gunzler, Steven A" sort="Gunzler, Steven A" uniqKey="Gunzler S" first="Steven A." last="Gunzler">Steven A. Gunzler</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kirchhoff, Trish" sort="Kirchhoff, Trish" uniqKey="Kirchhoff T" first="Trish" last="Kirchhoff">Trish Kirchhoff</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hogarth, Penelope" sort="Hogarth, Penelope" uniqKey="Hogarth P" first="Penelope" last="Hogarth">Penelope Hogarth</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weaver, Jerry L" sort="Weaver, Jerry L" uniqKey="Weaver J" first="Jerry L." last="Weaver">Jerry L. Weaver</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Krams, Michael" sort="Krams, Michael" uniqKey="Krams M" first="Michael" last="Krams">Michael Krams</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jamerson, Brenda" sort="Jamerson, Brenda" uniqKey="Jamerson B" first="Brenda" last="Jamerson">Brenda Jamerson</name>
<affiliation><inist:fA14 i1="03"><s1>VA Medical Center Geriatric Research, Education and Clinical Center and Department of Clinical Research, Campbell University School of Pharmacy</s1>
<s2>Morrisville, NC</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menniti, Frank S" sort="Menniti, Frank S" uniqKey="Menniti F" first="Frank S." last="Menniti">Frank S. Menniti</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Landen, Jaren W" sort="Landen, Jaren W" uniqKey="Landen J" first="Jaren W." last="Landen">Jaren W. Landen</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amnesia</term>
<term>Dyskinesia</term>
<term>Glutamate</term>
<term>Levodopa</term>
<term>NMDA</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Parkinsonism</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Parkinsonisme</term>
<term>Maladie de Parkinson</term>
<term>Amnésie</term>
<term>Pathologie du   système nerveux</term>
<term>NMDA</term>
<term>Glutamate</term>
<term>Lévodopa</term>
<term>Sousunité NR2B</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101,606, on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101,606 reduced the maximum severity of levodopa-induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>13</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>NUTT (John G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GUNZLER (Steven A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KIRCHHOFF (Trish)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HOGARTH (Penelope)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WEAVER (Jerry L.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KRAMS (Michael)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>JAMERSON (Brenda)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MENNITI (Frank S.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>LANDEN (Jaren W.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>VA Medical Center Geriatric Research, Education and Clinical Center and Department of Clinical Research, Campbell University School of Pharmacy</s1>
<s2>Morrisville, NC</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>1860-1866</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000184468160100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>32 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0522202</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101,606, on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101,606 reduced the maximum severity of levodopa-induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Amnésie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Amnesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Amnesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>NMDA</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>NMDA</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>NMDA</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Glutamate</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Glutamate</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Glutamato</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Sousunité NR2B</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Aminoacide excitateur</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Excitatory aminoacid</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aminoácido excitador</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Trouble de la mémoire</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Memory disorder</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Trastorno memoria</s0>
<s5>46</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Trouble cognitif</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Cognitive disorder</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Trastorno cognitivo</s0>
<s5>47</s5>
</fC07>
<fN21><s1>343</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0522202 INIST</NO>
<ET>Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism</ET>
<AU>NUTT (John G.); GUNZLER (Steven A.); KIRCHHOFF (Trish); HOGARTH (Penelope); WEAVER (Jerry L.); KRAMS (Michael); JAMERSON (Brenda); MENNITI (Frank S.); LANDEN (Jaren W.)</AU>
<AF>Department of Neurology, Oregon Health and Science University/Portland, Oregon/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut.); Pfizer Global Research and Development/Groton, Connecticut/Etats-Unis (5 aut., 6 aut., 8 aut., 9 aut.); VA Medical Center Geriatric Research, Education and Clinical Center and Department of Clinical Research, Campbell University School of Pharmacy/Morrisville, NC/Etats-Unis (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 13; Pp. 1860-1866; Bibl. 32 ref.</SO>
<LA>Anglais</LA>
<EA>Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101,606, on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101,606 reduced the maximum severity of levodopa-induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects.</EA>
<CC>002B17; 002B02U01</CC>
<FD>Dyskinésie; Parkinsonisme; Maladie de Parkinson; Amnésie; Pathologie du   système nerveux; NMDA; Glutamate; Lévodopa; Sousunité NR2B</FD>
<FG>Aminoacide excitateur; Neurotransmetteur; Syndrome extrapyramidal; Mouvement involontaire; Trouble neurologique; Pathologie de l'encéphale; Maladie dégénérative; Pathologie du   système nerveux central; Trouble de la mémoire; Trouble cognitif</FG>
<ED>Dyskinesia; Parkinsonism; Parkinson disease; Amnesia; Nervous system diseases; NMDA; Glutamate; Levodopa</ED>
<EG>Excitatory aminoacid; Neurotransmitter; Extrapyramidal syndrome; Involuntary movement; Neurological disorder; Cerebral disorder; Degenerative disease; Central nervous system disease; Memory disorder; Cognitive disorder</EG>
<SD>Disquinesia; Parkinson síndrome; Parkinson enfermedad; Amnesia; Sistema nervioso patología; NMDA; Glutamato; Levodopa</SD>
<LO>INIST-20953.354000184468160100</LO>
<ID>08-0522202</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001086 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001086 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0522202
   |texte=   Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism

Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri